JP2013540803A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013540803A5 JP2013540803A5 JP2013535462A JP2013535462A JP2013540803A5 JP 2013540803 A5 JP2013540803 A5 JP 2013540803A5 JP 2013535462 A JP2013535462 A JP 2013535462A JP 2013535462 A JP2013535462 A JP 2013535462A JP 2013540803 A5 JP2013540803 A5 JP 2013540803A5
- Authority
- JP
- Japan
- Prior art keywords
- tnf
- antagonist
- pharmaceutical composition
- composition according
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 8
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 claims 8
- 230000003042 antagnostic Effects 0.000 claims 8
- 239000005557 antagonist Substances 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 5
- 108010007562 Adalimumab Proteins 0.000 claims 2
- 206010003246 Arthritis Diseases 0.000 claims 2
- 108010008165 Etanercept Proteins 0.000 claims 2
- 210000002744 Extracellular Matrix Anatomy 0.000 claims 2
- 108010053490 Infliximab Proteins 0.000 claims 2
- 208000009975 Plantar Fibromatosis Diseases 0.000 claims 2
- 229960002964 adalimumab Drugs 0.000 claims 2
- 239000000853 adhesive Substances 0.000 claims 2
- 230000001070 adhesive Effects 0.000 claims 2
- 230000015556 catabolic process Effects 0.000 claims 2
- 230000004059 degradation Effects 0.000 claims 2
- 238000006731 degradation reaction Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229960000403 etanercept Drugs 0.000 claims 2
- 229960000598 infliximab Drugs 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000001519 tissues Anatomy 0.000 claims 1
Claims (11)
- TNF-αアンタゴニストを含む、初期段階のデュピュイトラン病、足底線維腫症又は癒着性関節包炎の処置用医薬組成物。
- デュピュイトラン病処置用である請求項１記載の医薬組成物。
- 疾患部位又はその症状が発現している部位に局所投与するためのものである請求項１又は２記載の医薬組成物。
- TNF-αアンタゴニストは、患者の手の中の患部組織に直接注射される請求項１〜３のいずれか１項に記載の医薬組成物。
- TNF-αアンタゴニストは、患者の手の中の臨床的な結節中に、又はそれに隣接する部位に注射により投与される請求項４記載の医薬組成物。
- TNF-αアンタゴニストは、酵素媒介細胞外マトリックス分解を伴う補助的及び／又は併用処置と共に、主たる処置として投与される請求項１〜５記載の医薬組成物。
- TNF-αアンタゴニストと、細胞外マトリックス分解、枯渇又は開裂剤とを含む請求項６記載の医薬組成物。
- TNF-αアンタゴニストが、インフリキシマブ、アダリムマブ、セルトリズマブペゴール、ゴリムバム及びエタネルセプトから選ばれる１又は複数である請求項１〜７のいずれか１項に記載の医薬組成物。
- TNF-αアンタゴニストの、初期段階のデュピュイトラン病、足底線維腫症又は癒着性関節包炎の処置用医薬の製造のための使用。
- 前記医薬が、初期段階のデュピュイトラン病治療用である請求項９記載の使用。
- TNF-αアンタゴニストが、インフリキシマブ、アダリムマブ、セルトリズマブペゴール、ゴリムバム及びエタネルセプトから選ばれる１種である請求項９記載の使用。
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1018325.9A GB201018325D0 (en) | 2010-10-30 | 2010-10-30 | Treatment for dupuytren's disease |
| GB1018325.9 | 2010-10-30 | ||
| GB1018362.2 | 2010-11-01 | ||
| GBGB1018362.2A GB201018362D0 (en) | 2010-11-01 | 2010-11-01 | Treatment of dupuytren's disease |
| GBGB1113718.9A GB201113718D0 (en) | 2011-08-10 | 2011-08-10 | Treatment of Dupuytren's Disease |
| GB1113718.9 | 2011-08-10 | ||
| PCT/EP2011/069147 WO2012056044A1 (en) | 2010-10-30 | 2011-10-31 | Treatment for dupuytren's disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016166524A Division JP2017014266A (ja) | 2010-10-30 | 2016-08-29 | デュピュイトラン病の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013540803A JP2013540803A (ja) | 2013-11-07 |
| JP2013540803A5 true JP2013540803A5 (ja) | 2014-12-18 |
| JP6004494B2 JP6004494B2 (ja) | 2016-10-12 |
Family
ID=44913268
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013535462A Active JP6004494B2 (ja) | 2010-10-30 | 2011-10-31 | デュピュイトラン病の治療 |
| JP2016166524A Pending JP2017014266A (ja) | 2010-10-30 | 2016-08-29 | デュピュイトラン病の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016166524A Pending JP2017014266A (ja) | 2010-10-30 | 2016-08-29 | デュピュイトラン病の治療 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US9138458B2 (ja) |
| EP (1) | EP2632446B1 (ja) |
| JP (2) | JP6004494B2 (ja) |
| AU (2) | AU2011322482B2 (ja) |
| CA (1) | CA2847197C (ja) |
| DK (1) | DK2632446T3 (ja) |
| ES (1) | ES2715204T3 (ja) |
| RU (1) | RU2013123796A (ja) |
| WO (1) | WO2012056044A1 (ja) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2632446T3 (en) | 2010-10-30 | 2019-04-01 | Univ Oxford Innovation Ltd | TREATMENT OF DUPUYTRY CONTRACT |
| JP2015521169A (ja) | 2012-05-01 | 2015-07-27 | プロテオリース リミテッド | 抜歯する方法 |
| US20130297023A1 (en) * | 2012-05-07 | 2013-11-07 | Hee-Jeong Im Sampen | Methods and Devices For Treating Intervertebral Disc Disease |
| WO2015006469A2 (en) * | 2013-07-11 | 2015-01-15 | 180 Therapeutics Lp | Method of treating fibroproliferative disorders including dupuytren ' s disease with one or more specific human matrix metalloproteinase and a tnf antagonist |
| US20180036404A1 (en) | 2015-03-02 | 2018-02-08 | 180 Therapeutics Lp | Method of treating a localized fibrotic disorder using a tnf receptor 2 antagonist |
| CA3020327A1 (en) | 2016-04-08 | 2017-10-12 | 180 Therapeutics Lp | Method of treating early stage dupuytren's disease |
| WO2018045213A1 (en) * | 2016-09-02 | 2018-03-08 | 180 Therapeutics Lp | Method of treating systemic fibrotic disorders using an il-33/tnf bispecific antibody |
| EP3570865A4 (en) * | 2016-09-02 | 2020-05-20 | 180 Therapeutics LP | METHOD FOR THE TREATMENT OF LOCALIZED FIBROTIC DISORDERS USING A BISPECIFIC ANTI-IL-33 / TNF ANTIBODY |
| US11564963B2 (en) | 2017-11-22 | 2023-01-31 | Progeneron, Llc | Topical compositions, process of large-scale manufacture, and method of use |
| WO2020247808A1 (en) * | 2019-06-07 | 2020-12-10 | Dale Biotech, Llc | Method for treating dupuytren's disease |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1132471A3 (de) * | 1989-09-12 | 2001-11-28 | F. Hoffmann-La Roche Ag | TNF-bindende Proteine |
| US5656272A (en) * | 1991-03-18 | 1997-08-12 | New York University Medical Center | Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies |
| GB9405076D0 (en) * | 1994-03-16 | 1994-04-27 | Inst Of Ophtalmology | A medical use of matrix metalloproteinase inhibitors |
| US6486140B2 (en) | 1994-07-19 | 2002-11-26 | Medicarb Ab | Agents, and methods employing them, for the prevention or reduction of tissue adhesion at a wound site |
| US5589171A (en) | 1994-08-22 | 1996-12-31 | Advance Biofactures Of Curacao | Treatment of Dupuytren's disease with collagenase |
| US6090382A (en) * | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| CN1083337C (zh) | 1996-03-26 | 2002-04-24 | 精工爱普生株式会社 | 打印装置及其控制方法 |
| US6086872A (en) | 1997-03-27 | 2000-07-11 | Advance Biofactures Of Curacao, Nv | Amelioration of dupuytren's disease |
| US6031005A (en) * | 1998-08-03 | 2000-02-29 | Easterling; W. Jerry | Composition and method for treating Peyronie's disease and related connective tissue disorders |
| US6060474A (en) * | 1998-11-05 | 2000-05-09 | New York Society For The Relief Of The Ruptured And Crippled Maintaining The Hospital For Special Surgery | Method for preventing scar tissue formation |
| GB0105330D0 (en) | 2001-03-02 | 2001-04-18 | Renovo Ltd | Genetic testing |
| US7754217B2 (en) * | 2001-03-16 | 2010-07-13 | Bio3 Research Srl | HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases |
| WO2002087576A1 (en) * | 2001-04-30 | 2002-11-07 | Arachnova Therapeutics Ltd. | The treatment of scarring and related conditions using ppar-gamma activators |
| US7553488B2 (en) | 2002-07-05 | 2009-06-30 | UNIVERSITé LAVAL | Antibodies against S100A8 and S100A9 proteins for modulating inflammatory reactions |
| GB0306165D0 (en) | 2003-03-18 | 2003-04-23 | Delta G Ltd | Medical treatment |
| US20080025986A1 (en) * | 2003-06-06 | 2008-01-31 | Ozes Osman N | Methods of Treating Tnf-Mediated Disorders |
| CA2536096A1 (en) | 2004-01-30 | 2005-08-18 | Angiotech International Ag | Compositions and methods for treating contracture |
| AU2006206393B2 (en) * | 2005-01-21 | 2010-04-08 | The Research Foundation Of State University Of New York | Methods for treating adhesive capsulitis |
| US7431927B2 (en) * | 2005-03-24 | 2008-10-07 | Epitomics, Inc. | TNFα-neutralizing antibodies |
| WO2010102262A1 (en) | 2009-03-06 | 2010-09-10 | Halozyme, Inc. | Temperature sensitive mutants of matrix metalloprotease 1 und uses thereof |
| EP2403353B1 (en) | 2009-03-06 | 2019-08-14 | Kenneth William Gregg | Composition for controlling fish |
| DK2632446T3 (en) | 2010-10-30 | 2019-04-01 | Univ Oxford Innovation Ltd | TREATMENT OF DUPUYTRY CONTRACT |
-
2011
- 2011-10-31 DK DK11779628.4T patent/DK2632446T3/en active
- 2011-10-31 CA CA2847197A patent/CA2847197C/en active Active
- 2011-10-31 AU AU2011322482A patent/AU2011322482B2/en active Active
- 2011-10-31 US US13/882,262 patent/US9138458B2/en active Active
- 2011-10-31 JP JP2013535462A patent/JP6004494B2/ja active Active
- 2011-10-31 RU RU2013123796/15A patent/RU2013123796A/ru not_active Application Discontinuation
- 2011-10-31 WO PCT/EP2011/069147 patent/WO2012056044A1/en active Application Filing
- 2011-10-31 ES ES11779628T patent/ES2715204T3/es active Active
- 2011-10-31 EP EP11779628.4A patent/EP2632446B1/en active Active
-
2015
- 2015-09-11 US US14/852,442 patent/US10273296B2/en active Active
-
2016
- 2016-08-29 JP JP2016166524A patent/JP2017014266A/ja active Pending
-
2017
- 2017-06-23 AU AU2017204267A patent/AU2017204267B2/en active Active
-
2019
- 2019-04-30 US US16/399,547 patent/US10669334B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013540803A5 (ja) | ||
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| MX2010004281A (es) | Composiciones y metodos para el tratamiento de la retinopatia diabetica. | |
| EA201290171A1 (ru) | Вводимые перорально кортикостероидные композиции | |
| WO2009021521A3 (en) | Use of gaboxadol for the manufacture of a medicament for treating stress-mediated depression | |
| EA200700214A1 (ru) | Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией | |
| BR112014006684A2 (pt) | análogos de glucagon | |
| EA201891154A1 (ru) | Ингибиторы рециклинга желчных кислот при лечении холестатических заболеваний печени у детей | |
| RU2013123796A (ru) | Способ лечения болезни дюпюитрена | |
| EA201270292A1 (ru) | Терапия глатирамером ацетатом с низкой кратностью | |
| EA201170669A1 (ru) | Лечение пирфенидоном пациентов с атипичной функцией печени | |
| EA201300121A1 (ru) | Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения | |
| WO2009093119A3 (en) | Use of serine protease inhibitors in the treatment of skin diseases | |
| BR112015010396A2 (pt) | terapia de combinação | |
| MY166890A (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| DE602006014691D1 (de) | DIAGNOSE, BEHANDLUNG UND PRÄVENTION VON GEFÄSSERKRANKUNGEN MITTELS IL-1alpha-AUTOANTIKÖRPERN | |
| EA201490163A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| WO2012007159A3 (en) | Novel gastro-retentive dosage forms | |
| MX2012006744A (es) | Tiazolidinadionas reguladores de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de diabetes mellitus y otras enfermedades metabolicas. | |
| JP2013503165A5 (ja) | ||
| BR112012030641A2 (pt) | métodos e composições para terapia farmacêutica oral | |
| RU2015127834A (ru) | Способы лечения диабета путем введения антагониста рецептора глюкагона в сочетании с ингибитором поглощения холестерина | |
| MX342020B (es) | Apolipoproteina a-iv como un peptido antidiabetico. | |
| AR081925A1 (es) | Uso de ranolazina para el tratamiento de la hipertension pulmonar | |
| RU2013147196A (ru) | Агонист рецептора 5-нт4 в качестве прокинетического агента |